

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Ampicillin Capsules BP 250 mg

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each capsule contains Ampicillin Trihydrate equivalent to 250 mg of Ampicillin.

For full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Capsule, hard (Capsule)

An opaque capsule with a grey cap and a red body with 'AMP 250' printed on the capsule shell and containing a white to creamy granular powder.

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

Ampicillin capsules BP are indicated for the oral therapy of bacterial infections caused by ampicillin-sensitive organisms. Such indications include infections of the upper and lower respiratory tract, genito-urinary tract and the gastro-intestinal tract. Specific indications include ear and soft tissue infections and gonorrhoea.

4.2 Posology and method of administration

Usual Adult/Elderly Dosage

The usual dosage is 250mg every 6 hours.

All recommended dosages below are a guide only. In severe infections, the dosages may be increased at the direction of the physician. Doses should be taken half to one hour before meals.

Consideration should be given to official guidance on the appropriate use of antibacterial agents. Consult local or national prescribing guidelines for antibiotic use before prescribing. Where possible, use only where antibiotic sensitivity is known or suspected.

Ear, nose and throat infections:	250mg four times a day
Bronchitis: Routine therapy:	250mg four times daily
High dose therapy:	1g four times a day
Pneumonia:	500mg four times daily
Urinary tract infections:	500mg three times daily

Gastro-intestinal infections: 500 - 750mg three to four times daily

Enteric fevers:

Acute: 1-2g four times daily for two weeks

Carriers: 1-2g four times daily for four to 12 weeks

Gonorrhoea: 2g orally with 1g probenecid as a single dose. Repeat doses are recommended for the treatment of females.

Usual children's dosage: (Under 10 years)

Half of the adult dosage

Renal Impairment:

In severe renal impairment (ie, creatinine clearance <10 mL/min) reduction in dose or extension of the dose interval should be considered. In patients undergoing dialysis, an additional dose should be administered after dialysis.

For oral administration only

4.3 Contraindications

Use in patients with hypersensitivity to penicillins, ampicillin, cephalosporins or any of the excipients.

4.4 Special warnings and precautions for use

Before initiating therapy with ampicillin, careful enquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.

Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported in patients receiving beta-lactam antibiotics. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of beta-lactam hypersensitivity.

Prolonged use of an anti-infective may occasionally result in the development of super-infection due to organisms resistant to that anti-infective e.g. *Candida* or *Pseudomonas*.

Care should be taken with patients with renal impairment and dose adjustment may be required (see section 4.2)

Care should be taken when high doses are given; renal and haematological status should be monitored during high-dose and prolonged therapy.

Ampicillin should be avoided in glandular fever, cytomegalovirus (CMV), and/or acute and chronic lymphatic leukaemia and possibly HIV as erythematous rashes are more common.

Care is necessary when treating spirochaete infections particularly Syphilis.

4.5 Interaction with other medicinal products and other forms of interaction

Ampicillin may reduce the efficacy of oral contraceptives and patients should be warned accordingly.

Uricosurics: excretion of penicillin is decreased, giving an increased risk of toxicity e.g. Probenecid and sulfinpyrazone.

Allopurinol increases Ampicillin induced skin reactions.

Anti-coagulants: INR can be altered by the administration of Ampicillin while on Warfarin and Phenindione.

Vaccines: The efficacy of Oral Typhoid Vaccine may be reduced when ampicillin is coadministered

Cytotoxics: the excretion of methotrexate is reduced.

Chloroquine: absorption of ampicillin is reduced when taken concomitantly with chloroquine.

Bacteriostatic antibacterials such as erythromycin, chloramphenicol and tetracycline may interfere with the bactericidal action of ampicillin

As probenecid prolongs the half-life of this penicillin, it may be used therapeutically for this purpose.

Ampicillin may interfere with some diagnostic tests eg. tests for urinary glucose using copper sulphate; direct anti-globulin (Coombs' test) and some tests for urinary or serum proteins. Tests using bacteria, eg. the Guthrie test for phenylketonuria using *Bacillus Subtilis* organisms, could also be affected while patients are taking penicillins.

4.6 Fertility, pregnancy and lactation

Pregnancy:

Animal studies with ampicillin have shown no teratogenic effects. The product has been in extensive clinical use since 1961 and its use in human pregnancy has been well documented in clinical studies. When antibiotic therapy is required during pregnancy, ampicillin may be considered appropriate.

Lactation:

During lactation, trace quantities of penicillins can be detected in breast milk. Adequate human and animal data on use of ampicillin during lactation are not available.

4.7 Effects on ability to drive and use machines

None

4.8 Undesirable effects

Side effects as with other penicillins are rare and usually of a mild or transitory nature. Occasionally, gastro-intestinal disturbances, nausea, vomiting and diarrhoea or haemorrhagic colitis or pseudomembranous colitis may occur.

Erythematous maculo-papular rashes, sore mouth and sore, black, hairy tongue have occurred. Two types of rashes have been observed: an urticarial rash which is usually indicative of true penicillin hypersensitivity and an erythematous rash which is generally specific to ampicillin. The latter is particularly seen in patients with infectious mononucleosis, cytomegalovirus, acute and chronic lymphatic leukaemia and possibly HIV. Erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis has been reported. If a rash occurs, treatment should be discontinued.

Angioedema and anaphylaxis (see section 4.4) have occasionally occurred.

Fever, joint pains, serum sickness-like symptoms have been reported.

There have been reports of haemolytic anaemia, thrombocytopenia, leucopenia, neutropenia and coagulation disorders. Prolongation of bleeding time and prothrombin time have also been reported rarely.

Particularly with high doses or in renal impairment, CNS toxicity including convulsions have occurred; with prolonged use paraesthesia.

Nephropathy and interstitial nephritis has been reported.

Hepatic effects: As with other beta-lactam antibiotics, hepatitis and cholestatic jaundice have been reported rarely. As with most other antibiotics, a moderate and transient increase in transaminases has been reported.

4.9 Overdose

Gastrointestinal effects such as nausea, vomiting and diarrhoea may be evident and should be treated symptomatically.

Ampicillin may be removed from the circulation by haemodialysis.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

ATC Code: J01CA01

Ampicillin is employed in the treatment of infections of the urinary tract due to gram-negative organisms, especially *Escherichia coli*, *Proteus mirabilis* and enterococci resistant to benzylpenicillin; it is used for the prophylaxis and treatment of the respiratory tract such as chronic bronchitis, pneumonia and bronchiectasis.

Because it is excreted in high concentration in the bile it has been used in the treatment of infections of the biliary and intestinal tracts caused by *E. Coli*, *Salmonella* and *Shigellae*. Because of its low toxicity and broad antimicrobial spectrum, it has been added to fluids used for intraperitoneal dialysis to prevent the development of bacterial peritonitis.

5.2 Pharmacokinetic properties

Ampicillin is relatively stable in the acid gastric secretion and is moderately well absorbed from the gastro-intestinal tract after oral administration. Peak concentrations in serum are obtained in about 1 or 2 hours and are reported to range from 0.8 to 8.5 µg per ml. About 20% is bound to plasma proteins in the circulation. It diffuses across the placenta and high concentrations are found in cerebrospinal fluid when the meninges are infected. About 30% of an orally administered dose is excreted in the urine in 6 to 8 hours; urinary concentrations range from 0.25 to 2.5 mg per ml. A high concentration is reached in bile.

5.3 Preclinical safety data

Not applicable.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Magnesium stearate

Capsule shell:

Gelatin

Black Iron Oxide (E172)

Titanium Dioxide (E171)

Erythrosine (E127)

Patent Blue V (E131)

Quinoline Yellow (E104)

6.2 Incompatibilities

Not applicable.

6.3 Shelf Life

2 years.

6.4 Special precautions for storage

Store below 25°C.

Keep the container tightly closed in order to protect from moisture.

6.5 Nature and contents of container

The product is stored in polypropylene jars with polyethylene caps containing 100, 500 and 1,000 capsules. Not all pack sizes may be marketed.

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

No special requirements.

7 MARKETING AUTHORISATION HOLDER

Athlone Laboratories Limited
Ballymurray
Co. Roscommon

8 MARKETING AUTHORISATION NUMBER

PA0298/001/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 29 May 1981

Date of last renewal: 29 May 2006

10 DATE OF REVISION OF THE TEXT

October 2010